New evidence shows tirzepatide and semaglutide strongly protect the heart

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs.